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尿細管上皮細胞における
Connective Tissue Growth Factor （CTGF）発現の検討
小林　竜也
Expression of Connective Tissue Growth Factor in Renal Tubular Epithelial Cells
Tatsuya Kobayashi (Department of Nephrology, Saitama Medical School, Moroyama, Iruma -gun, Saitama 
350 -0495, Japan)
Background/Purpose: Connective tissue growth factor (CTGF) is a member of CCN family which mediates 
profibrotic effects of transforming growth factor -β1 (TGF-β1), promoting fibroblast proliferation and extracellular 
matrix (ECM) production. CTGF has been presumed to involve in a variety of organ fibrogenesis. In the kidney at 
health and a disease, by using in situ hybridization glomerular parietal and visceral epithelial cells, mesangial cells, 
and interstitial fibroblasts were shown to express CTGF. Recently, tubular epithelial cells have been also revealed 
to express CTGF especially in diabetic nephropathy. Therefore, in this study, I evaluated CTGF protein expression 
in the tubular epithelium of renal biopsy specimens by immunohistochemistry, and the expression regulation 
and the role of CTGF in the cultured tubular epithelial cells (mPTEC). Methods: Using an anti -CTGF antibody, 
I performed catalyzed signal amplification immunohistochemistry on renal biopsy specimens from patients with 
minimal change nephrotic syndrome (MCNS), diffuse proliferative lupus nephritis (DPLN), IgA nephropathy 
(IgAN), and diabetic nephropathy (DN). Using mPTEC cultured in monolayer and co - culture with renal fibroblasts 
(TFB), whether a given humoral factor could induce CTGF mRNA expression and whether CTGF derived from 
mPTEC could stimulate TFB to produce type I collagen were tested. The expression of mRNA and type I collagen 
were determined by ribonuclease protection assay and indirect enzyme - linked immunosorbent assay, respectively. 
Results: Significant CTGF expression in the tubular epithelium was found in parallel to the interstitial fibrosis 
in DN samples. In addition, it was revealed that glucocorticoid (GC) therapy resulted in significant induction of 
tubular CTGF expression in MCNS and DPLN. Among profibrotic growth factors and proinflammatory cytokines 
employed, only TGF-β1 could induce CTGF mRNA expression in mPTEC in time -  and dose -dependent fashion. 
D -glucose and dexamethasone could also induce CTGF expression in mPTEC. CTGF derived from mPTEC by 
TGF-β1 and d -glucose could subsequently induce type I collagen production in TFB. Conclusion: Renal tubular 
epithelial cells can express CTGF in vivo and in vitro, which is likely involved in renal fibrogenesis at least in DN 
and other diseases undergoing GC therapy. 
Keywords: connective tissue growth factor (CTGF), tubular epithelial cells, transforming growth factor -β(TGF-
β), d -glucose, glucocorticoid (GC) 
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果たす 増殖因子 として transforming growth factor -β







connective tissue growth factor （CTGF）6 -8) に着目し，
検討を進めている．CTGFは 349個のアミノ酸よりな
る 36～ 38kDのペプチドであり，近年多数の類似する
分子が登録されている CTGF/fisp12, cyr61, nov（CCN）
ファミリーの一員である．ヒト CTGFは 1991年にヒ
ト臍帯静脈内皮細胞の cDNAライブラリーより9)，また
























































ゾロン 1 mg/kg -wt/日）の症例も含めた．また IgAN
の診断では，SLE，肝疾患，Schoenlein -Henoch紫斑
病は除外した．各患者の臨床／病理パラメーターを









ターに取り込み，画像処理ソフト（Mac SCOPE, Ver. 
2.5, Mitani Corp., Fukui, Japan）を用い定量化し19)，陽性




分間 3回，75％ EtOH 10分間 1回，distilled water 5分
間 3回，Phosphate -buffered saline （PBS）5分間）を
行った．その後，抗原活性化のためクエン酸緩衝液
中（10 mM sodium citrate buffer pH 6.0）でマイクロ
ウエーブ煮沸した（600 W 10分間 3回）．以下の行
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程は Biotin Blocking Systemキットおよび Catalyzed 
Signal Amplification （CSA） System Peroxidase
キット（DAKO, Carpinteria, CA, USA）を用いて行っ
た．また洗浄には TBST液（0.05 M Tris -HCl pH 7.6, 










クローナル抗体（American Qualex, San Clement, CA, 
USA）を用い室温で 1時間反応させた．洗浄後（10分















り御供与頂いた21, 22)．共に，Dulbecco’s Modified Eagle 
Medium （D-MEM），10％ fetal calf serum （FCS），100 






Table 1. Clinical and pathological parameters of patients at biopsy
n.c., not checked; n.d., not detected; PSL, administered prednisolone; Glo, glomerulus; TubInt, tubulointerstitium; Epi, 
glomerular epithelium; Mes, mesangium cell; Tub, tubular epithelium; Int, interstitial cells; (＋), faint; (＋＋), moderate; (＋＋
＋), strong. *presented cases
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m P T E C単層培養系：6 -w e l l  p l a t eにm P T E Cを
15000 個/cm2の濃度で播種し，24時間後に resting 
mediumへ交換の後，48時間 resting したものを単
層培養系として実験に供した．使用した増殖因子／
サイトカインは，recombinant human CTGF （rhCTGF）
は岡山大学歯学部滝川正春教授から御供与頂き 20)，
その他recombinant human TGF -β1（rhTGF -β1），
recombinant human HGF（rhHGF），recombinant human 
EGF（rhEGF），recombinant human FGF-2 （rhFGF-2），
recombinant mouse IL -1β（rmIL -1β），recombinant 
rat PDGF-BB（rrPDGF），recombinant mouse TNF-α
（rmTNF-α）はすべて R&D Systems （Minneapolis, MN, 
USA）より購入した．また dexamethasone （DEX）およ
び d-glucose （GLC）は Sigma （St. Louis, MO, USA）より
購入し使用した．TGF-β1に関しては，反応時間およ
び投与濃度を変化させ，その他の液性因子（rhCTGF, 
rrPDGF, rhEGF, rhFGF, rhHGF, rmIL -1β, rmTNF -
α）については一定の刺激時間として投与濃度を変化
させ，また GLCに関しては anti -TGF-β中和抗体（IgG, 
50μg/ml）（Genzyme, Cambridge, MA, USA）を添加し
た検討も加えた．RNA抽出は以下に示す方法で行った．
mPTEC / TFB共培養系：6 -well plate に TFB を
15000 個 /cm2 の濃度で播種し，また 0.4μm pore 
size の culture inser t （FALCON CELL CULTURE 
INSERTS, BECTON DICKINSON, Franklin Lakes, NJ, 
USA）に mPTECを 30000個 /cm2 の濃度で播種し，
24 時間後に上記の TFB の 6 -well plate に重層し，
同時に resting mediumに交換の後，48時間 resting
したものを PTEC/TFB共培養系として実験に供した．
GLC 100 mM，GLC 100 mM＋anti -TGF-βあるいは
GLC 100 mM＋anti -TGF-β＋anti -CTGFを添加した
resting medium，および DEX 1000nMあるいは DEX 





Ribonuclease protection assay (RPA): 培養細胞
から TRIzol （GIBCO BRL, Grand Island, NY, USA）を
用いて total RNAを抽出し，試料とした．cRNA probe 
合成に用いた templateを以下に示す．Glyceraldehyde -
3 -phosphate dehydrogenase（GAPDH）（114 bp, 673 
to 787 corresponding to rat GAPDH）は 新 潟 大 学 腎
研究施設構造病理学分野 山本格教授から御供与頂
いた．CTGF （202 bp, 731 to 932 corresponding to mouse 
CTGF）は 当 教 室 で reverse transcriptase-polymerase 
chain reaction（RT-PCR）にて取得した．32P -UTP label
した cRNA probeと 10μgの total RNAを 45℃，16時
間 hybridizationの後，ribonuclease A （1.2μg/ml）お
よび ribonuclease T1 （120 U/ml）で 30℃，60分処理
した．Proteinase K（ 0.45μg/ml） 37℃， 60分処理に
て ribonucleaseを不活化し，EtOH 沈殿にて精製後，
6％の acrylamide変性ゲルを用いて protected -band 
を分離した．－ 80℃ で 3時間から 5日間または室温
8～ 24時間にて autoradiography の後，フィルムを透
過型 scanner （GT-9600, EPSON, Nagano, Japan）で取
り 込 み， 各 protected -band を NIH image （Ver.1.62, 
NIH Division of Computer Research and Technology, 
Bethesda, MD, USA）を用いて定量した．各 mRNA
量は，GAPDHとの比で標準化した．
Indirect enzyme - linked immunosorbent assay 
(ELISA): 培養上清を ELISA用 96 -well plate （Nunc -
Immuno Plate, Nalge Nunc International, Rochester, 
NY, USA）に各 200μl分注し，37℃，60分間 incubate
して可溶性蛋白の coating を行った．Coating 後，





Temecula, CA, USA）を加え室温で 30分間反応後，5回
洗浄し，alkaline phosphatase化抗ウサギ IgGヤギポ
リクローナル抗体（1:3000; Sigma）にて室温で 30分間







に関しては，計算には Stat View （Macintosh Version 
1.03, Abacus Concepts, Berkeley, CA, USA）を使用し
















































































および rmIL -1βによる有意な CTGF mRNA発現誘導
は認められなかった（Fig.  4）．
3） d -Glucose  （GLC）
GLC濃度 30 mMまでの刺激では有意な CTGF 
mRNA発現は認められなかったが，100 mMにおいて






4） Dexamethasone  （DEX）
DEX刺激により mPTECにおける CTGF mRNA発








rhTGF-β1 （3 ng/ml）をmPTECおよび TFBの共培
養系に投与すると，TFB単層培養に比較して有意な 1
型コラーゲン産生亢進が認められた（Fig. 7）．この効果






















Fig. 1. Identification of CTGF protein expression in renal biopsy specimens by catalyzed signal amplification 
immunohistochemstry. ( a, b, c, d, e, f; DAB, x200. g, h; MT, x200) a. A typical case of untreated MCNS. No CTGF expression was 
observed even in the glomerular epithelial cells. b. Another case of MCNS treated with glucocorticoid. Tubular expression of 
CTGF was found, and CTGF expression by glomerular parietal and visceral epithelium was rescued. c. A typical case of untreated 
DPLN. CTGF expression was observed in the glomerular cells, but not in the tubular epithelial cells. d. Another case of DPLN 
treated with glucocorticoid. Significant tubular expression of CTGF was found. Some interstitial cells were also positive for 
CTGF(arrows). e. A typical case of IgAN. CTGF expression was occasionally observed in glomerular parietal and visceral epithelial 
cells and interstitial cells. f. A typical case of DN. Not only glomerular cells, but also tubular epithelial cells, interstitial cells (arrows) 
and vascular endothelial cells were revealed to express CTGF significantly. g,h. Quantitative analysis of histopathology by light -
microscopy. A target area was measured quantitatively by a computer -assisted image analyzer (MacSCOPE), which focused on the 
blue area of fibrosis(g), which then turned to green(h). The analyzer calculated the percentage of this green area (22%~).
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れていない複雑な病態に関与している可能性が示唆
された．Fig. 9にマウス CTGF遺伝子の 5’側上流域
に存在する主要な転写調節部位を示す（[gb:M70641]）．
Grotendorstらは CTGFの強力な発現誘導因子である








ン酸化 Smad3/Smad4の Smad binding element （SBE）
への結合によると報告している24)．実際，強皮症患者




Fig. 2. Regression between fibrotic area and tubuler CTGF expression. a. Cases with DPLN. A significant correlation was 
observed between fibrotic area and tubuler CTGF expression. b. Cases with DN. Fibrotic area was likely correlated with tubuler 
CTGF expression. 
Fig. 3. Quantification of CTGF mRNA expression in mPTEC treated with a profibrotic growth factor, rhTGF-β1. Expression of 
CTGF mRNA in mPTEC was induced by 3 hr treatment with rhTGF-β1 in a dose -dependent fashion and achieved to the peak 
at 3ng/ml of rhTGF-β1 (a ). The peak expression of CTGF in mPTEC by rhTGF-β1 (3ng/ml) occurred after 3 to 6 hr (b). A 
representative blot (a, & b) selected from 3 separate experiments was shown, and the densitometric data here were obtained 
from these 3 blots.
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Fig. 5. Quantification of CTGF mRNA expression in mPTEC 
treated with d -glucose (GLC). Expression of CTGF mRNA in 
mPTEC was significantly induced by 3 hr treatment with GLC 
in a dose -dependent fashion. A peak expression of CTGF was 
obtained by GLC at 100mM, which was not ameliorated by co -
administration with a neutralizing anti -TGF -β antibody. A 
representative blot selected from 3 separate experiments was 
shown, and the densitometric data here were obtained from 
these 3 blots.
Fig. 4. Quantification of CTGF mRNA expression in mPTEC 
treated with a proinflammator y cytokines, rmTNF -α. 
Expression of CTGF mRNA in mPTEC was not significantly 
induced by 3 hr treatment with rmTNF -α at various 
concentrations. A representative blot selected from 3 separate 
experiments was shown, and the densitometric data here 






細胞質中に浸透した GCが GCレセプタ （ーGR）に
結合後，核内に移行して標的遺伝子の発現調節領域
に存在する Glucocorticoid Response Element（GRE）
に結合し，その転写活性を促進させるというもので




流域に Signal Transducer and Transcription Activator 3 
Response Element （Stat3RE）を有し，ラット肝細胞に
おいては Stat3と GC-GR複合体との相互作用で GC
によるγフィブリノーゲン遺伝子発現促進が認めら



















た検討では TGF-β1および DEXによる CTGF遺伝














Fig. 6. Quantification of CTGF mRNA expression in mPTEC 
treated with dexamethasone (DEX). Expression of CTGF 
mRNA in mPTEC was significantly induced by 3 hr treatment 
with DEX in a dose -dependent fashion. A representative blot 
selected from 3 separate experiments was shown, and the 
densitometric data here were obtained from these 3 blots.
Fig. 7. Quantification of type I collagen protein (COLI) 
production by TFB by 48 hr after stimulation with rhTGF-β1 
in monolayer and co - culture with mPTEC. rhTGF-β1 (3ng/
ml) induced COLI in TFB monolayers, and significantly more 
COLI in TFB co -cultured with mPTEC. Co -administration 
with a neutralizing anti -CTGF antibody significantly 
ameliorated COLI production by TFB in co - culture. The data 
























































Fig. 8. Quantification of type I collagen protein (COLI) 
production by TFB by 48 hr after stimulation with d -glucose 
(GLC) in monolayer and co - culture with mPTEC. GLC 
(100mM) induced COLI in TFB monolayers, and significantly 
more COLI in TFB co -cultured with mPTEC. Neutralizing 
TGF -β1 slightly, and neutralizing both of TGF -β1 and 
CTGF significantly ameliorated COLI production by TFB 
in co - culture. The data shown here were obtained from 3 
independent experiments.
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